anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic Pain is one of the most common reasons adults seek medical care and has been linked to restrictions in mobility and daily activities, dependence on opioids, anxiety, depression, and poor perceived health or reduced quality of life. Currently, local pain clinic waitlists have thousands of patients with wait times between 1 to 3 years, with many receiving little to no specialized support while waiting for an appointment. To address this problem, this study assesses the impact of the MMP App to support the health and medication use of patients on the waitlist. Using this approach patients on the waitlist can use this app to report their pain, functionality, reflections, and medication use, as well as read educational resources about pain management.

This study tests the effectiveness of the MMP App versus a control group (i.e., standard practice) on health outcomes and mediation use over 60 days in a randomized control trial (RCT). The primary outcomes are pain, anxiety, pain self-efficacy, and quality of life. Secondary outcome is medication usage. Researchers will use descriptive and regression analysis to assess the data collected.
BACKGROUND: Dolichoectasia is a rare arterial condition characterized by the dilatation, tortuosity, and elongation of cerebral blood vessels. The vertebrobasilar artery and internal carotid artery are the common sites of dolichoectasia. However, dolichoectasia of the branch arteries, such as the ophthalmic artery (OA), is extremely rare. To the best of our knowledge, this is the first case of ophthalmic dolichoectasia that was successfully treated with endovascular internal coil trapping.
CASE PRESENTATION: A 54-year-old female patient presented with transient left ophthalmalgia and visual disturbance. Magnetic resonance imaging revealed a dilated and elongated left OA compressing the optic nerve at the entrance of the optic canal. However, a previous image that was taken 17 years back revealed that the OA was normal, which suggested the change in dolichoectasia was acquired. Cerebral angiography showed that the dilated and tortuous OA was running from the ophthalmic segment of the left internal carotid artery into the orbit. The symptoms could have been attributed to the direct compression of the dolichoectatic OA in the optic canal. A sufficient anastomosis between the central retinal artery and the middle meningeal artery was identified on external carotid angiography with balloon occlusion of the internal carotid artery. Endovascular treatment with internal trapping of the OA was performed due to ophthalmic symptom progression. Internal coil trapping of the OA was performed at the short segment between the OA bifurcation and the entrance of the optic canal. As expected, the central retinal artery was supplied via the middle meningeal artery after the treatment. The transient visual disturbance was immediately resolved. Ophthalmalgia worsened temporarily after the treatment. However, it completely resolved after several days of oral corticosteroid therapy. Postoperative angiography showed that the origin of the OA was occluded and that the OA in the optic canal was shrunk. The flow of the central retinal arteries via the middle meningeal artery was preserved.
CONCLUSIONS: OA dolichoectasia is rare, and its pathogenesis and long-term visual prognosis are still unknown. However, endovascular therapy can improve symptom by releasing the pressure site in the optic canal.
The invention relates to a medicament for treating cancer and a method for preparing the same. The medicament is prepared by following materials by weight: 20-60 portions of oldenlandia, 30-90 portions of barbat skullcap and 30-100 portion of asparagus. The preparing method is that: washing the oldenlandia and the barbat skullcap; decocting to liquid with water for standby; cooking the asparagus, smashing for standby; drinking the prepared oldenlandia and barbat skullcap liquor, and then taking the smashed asparagus with water, two times a day for 40 g per time. The orally taken health-care medicament can remove pain by diet therapy without any toxicity and side-effect for stomach cancer, rectum cancer, breast cancer, lymphoma, skin cancer, lung cancer, bladder cancer and cervix cancer. The medicament can promote qi and blood circulation, clear away heat-evil and expel superficial evils, diminish the inflammation and reduce the pain, dispel deposit and dissipate binds and remove cancer. The usefulness is high.
This trial is a one-year, cluster-randomized, partially masked, controlled trial among families living in rural, inland Timor-Leste. This trial aims to test and compare the effects of two treatments, alone and in combination, on the frequency and volume of household fish consumption in upland areas as a proxy for improved dietary diversity and micronutrient intake. Treatment 1 is the installation of nearshore, moored fish aggregating devices (FADs) to improve catch rates with existing fishing gears. Treatment 2 is social and behaviour change (SBC) activities to promote fish consumption. Villages in inland communities will be randomized to receive treatment 1, treatment 2, both treatments, or neither treatment. Some households with one child under five will be recruited, and data will be collected at baseline (prior to the rollout of the treatments) and endline. Our study will determine the impact of an improved supply of fish, along with nutrition-oriented SBC activities, on the fish purchasing and consumption practices of rural, inland households. Findings from this study are urgently needed by small island developing states in order to make policy and investment decisions on how best to improve households' diets using locally available, nutrient-dense foods such as fish. Investments such as these are needed to break the cycle of malnutrition.
AIM: Acute kidney injury (AKI) increases the risk for progressive chronic kidney disease (CKD). MicroRNA (miR)-486-5p protects against kidney ischemia-reperfusion (IR) injury in mice, although its long-term effects on the vasculature and development of CKD are unknown. We studied whether miR-486-5p would prevent the AKI to CKD transition in rat, and affect vascular function.
METHODS: Adult male rats were subjected to bilateral kidney IR followed by i.v. injection of liposomal-packaged miR-486-5p (0.5 mg/kg). Kidney function and histologic injury were assessed after 24 h and 10 weeks. Kidney endothelial protein levels were measured by immunoblot and immunofluorescence, and mesenteric artery reactivity was determined by wire myography.
RESULTS: In rats with IR, miR-486-5p blocked kidney endothelial cell increases in intercellular adhesion molecule-1 (ICAM-1), reduced neutrophil infiltration and histologic injury, and normalized plasma creatinine (P<0.001). However, miR-486-5p attenuated IR-induced kidney endothelial nitric oxide synthase (eNOS) expression (P<0.05). At 10 weeks, kidneys from rats with IR alone had decreased peritubular capillary density and increased interstitial collagen deposition (P<0.0001), and mesenteric arteries showed impaired endothelium-dependent vasorelaxation (P<0.001). These changes were inhibited by miR-486-5p. Delayed miR-486-5p administration (96 h, 3 weeks after IR) had no impact on kidney fibrosis, capillary density, or endothelial function.
CONCLUSION: In rats, administration of miR-486-5p early after kidney IR prevents injury, and protects against CKD development and systemic endothelial dysfunction. These protective effects are associated with inhibition of endothelial ICAM-1 and occur despite reduction in eNOS. miR-486-5p holds promise for the prevention of ischemic AKI and its complications.
One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
The invention relates to a process of modification of the nitrogen oxides metabolism by means of modification of the micellar catalysis parameters of NO oxidation. According to the invention, the number of phases and/or the volume ratio of the phases and/or the coefficients of distribution of NO and O2 between the phases are modified. The number of phases is modified by using perfluorocarbons, haloid derivatives thereof and perfluoralkylamines with a high coefficient of distribution of NO and O2, which are used as a hydrophobic phase for micellar analysis. The invention also relates to compositions used to vary the output of nitrite, nitrate, nitrosothiols and other oxidation products, whereby said compositions include emulsions of perfluororganic compounds, catalysts and inhibitors of excessive nitrosation, reducers, free radical scavengers and nitrosation targets which modify the balance of the nitrosated biogeneous compounds. The inventive methods for acting on a patient's organism include using such compositions together with variations in temperature and moisture and with traditional drugs. Independent claims in this invention also relate to the use of the known blood replacement substances containing perfluorated compounds and of the steam bath or the sauna in order to accelerate NO oxidation.
Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
NEW MATERIAL:A compound shown by the formula I (R1 is methyl, or ethyl; R2 is H, or 1-4C alkyl) and its salt. EXAMPLE:1-Ethyl-6-fluoro-7-(1-homopiperazinyl)-4-oxo-1,4-dihydroquinol ine-3-carboxylic acid. USE:A drug. Having a wide antibacterial action on Gram-positive and Gram-negative bacteria. PROCESS:A 7-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative shown by the formula II is reacted with a homopiperazine derivative shown by the formula III in the absence of a solvent or in the presence of a solvent such as an alcohol, ester, etc. at 100-180 deg.C, to give a compound shown by the formula I .
The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
BACKGROUND: Intraoperative neuroelectrophysiology monitoring (IONM) has been used to decrease complications and to increase the successful rate of microvascular decompression (MVD) MVD for hemifacial spasm (HFS). Still, it is not available at limited resource centers. We report the outcome of patients undergoing MVD for HFS without using IONM.
METHODS: The variables concerning the patients' demographics (age and gender), clinical characteristics, offending vessels (vertebral artery type and non-vertebral artery type), postoperative grade of HFS, and postoperative complications of HFS patients undergoing MVD were retrospectively reviewed and collected. The scoring system provided by the Japan Society for MVD was used to evaluate the postoperative outcome of HFS. Postoperative hearing ability was evaluated according to a subjective assessment of the patients.
RESULTS: A total of 228 patients were recruited. Their median age was 51.0 (44.0-57.0) years old. The total cure effect was observed in 207 (90.8%) patients within the first week after the surgery and in 200 (96.1%) patients in a 2-year follow-up. Permanent hearing disturbance happened in 2 patients (0.9%). No patient had permanent unilateral deafness (0%). No postoperative permanent facial paralysis was reported.
CONCLUSIONS: MVD without IONM may be performed safely and effectively to treat patients with HFS.
An analytics system creates a data structure counting strings of methylation vectors from a healthy control group. The analytics system enumerates possibilities of methylation state vectors given a sample fragment from a subject, and calculates probabilities for all possibilities with a Markov chain probability. The analytics system generates a p-value score for the subject's test methylation state vector by summing the calculated probabilities that are less than or equal to the calculated probability of the possibility matching the test methylation state vector. The analytics system determines the test methylation state vector to be anomalously methylated compared to the healthy control group if the p-value score is below a threshold score. With a number of such sample fragments, the analytics system can filter the sample fragments based on each p-value score. The analytics system can run a classification model on the filtered set to predict whether the subject has cancer.
Novel pharmaceutical compositions of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears or sinuses are disclosed. Novel Formulation (I) comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg/mL, a controlled tonicity within the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted composition is capable of long-term storage in the refrigerated state with a shelf life of up to 30 months. Formulation (I) may be delivered therapeutically either in a nebulized form or in a liquid form. Novel Formulation (II) comprises UTP in an aqueous solution having a therapeutic concentration approaching the limit of UTP's solubility at ambient temperature or in a suspension which exceeds drug solubility. This high concentration allows delivery of a therapeutic amount of UTP in very small volumes (50 to 100 .mu.L) suitable for administration via portable hand-held devices such as metered dose inhalers. Formulation (II) has extended shelf life without the need for refrigeration after being dispensed to the patient.
Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.
Blood donors at Oslo University Hospital (OUH) Blood Bank with self-reported birch pollen allergy and/or asthma were recruited for the study during last 4 months of 2015 and first 2 months of 2016. They signed an informed consent form for the study and were randomized into Andosan™ and placebo Groups. The PI (MD) had the study key and the participants in the study were handled by other staff (nurses and bioengineers) at the blood bank. The participants were given a questionnaire that was filled out before and after the study. Before, during and after the study also blood samples were taken for allergy testing (IgE, BAT) or cytokine profiles. When the participants visited the blood bank after 3.5 weeks, they brought the study medicine vessel (plastic container) that was controlled for remaining study medicine (all should have been used) and given new study medicine for the remaining study period (3.5 weeks). The participants were also asked about possible side effects of the study medicine. In the intervention arm, Agaricus blazei-based mushroom extract Andosan™, was given, which is produced as Health food in Japan and imported as food to Norway and provided for the study by Immunopharma company, Norway. Data were collected and analyzed together after the study. Statistical help was solicited from an OUH statistician.
The proposed study will be a randomized controlled trial design. Participants will be randomized to either a CBTI treatment or a wait list control condition. The intervention is SHUTi, a validated web based version of CBTI, which will take place over seven weeks and will include a combination of face to face and telephone sessions, and email updates. All participants will have a face to face meeting with the doctoral student at enrollment. During the intervention period, all participants will be contacted by telephone at week 1, 3, and 6 to check in and to encourage participant engagement. However, during phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study. Participants in SHUTi will additionally be provided the the doctoral student's phone number and will be encouraged to contact her if they have any questions during the intervention. They will also have the option of setting up appointments for face to face meetings during a clinic appointment if they desire additional therapist guidance. Pretreatment, all participants will complete a two week sleep diary and multiple self report measures. At the end of the intervention, all participants will complete a two week sleep diary and multiple self report measures again.
OBJECTIVES: Patients with von Willebrand disease (vWD) undergoing surgery are routinely treated with von Willebrand factor (vWF)/factor VIII (FVIII) concentrate to control bleeding risk, but consensus is lacking on optimal dosing. This study aimed to evaluate the efficacy and safety of tailored doses of vWF/FVIII concentrate according to intervention-associated bleeding risk in vWD patients undergoing surgery.
METHODS: This was a retrospective analysis of vWD patients who underwent surgical procedures at a haemophilia centre. Patients received vWF/FVIII concentrate with dosage and duration of treatment dependent on intervention type (dental, gynaecological, abdominal or orthopaedic/traumatic) and bleeding risk (moderate/high).
RESULTS: Eighty-three surgical procedures (42 patients) were included. Median preoperative loading doses of vWF/FVIII concentrate were 29.9 IU/kg and 35.7 IU/kg for interventions with moderate ( n  = 16) or high ( n  = 67) bleeding risk, respectively. The median perioperative dose was highest in orthopaedic or trauma-related surgery (140 IU/kg) and lowest in dental or gynaecological interventions (76.4 IU/kg and 80.0 IU/kg, respectively). During follow-up, no bleeding or other complications were observed in 95% of patients.
CONCLUSIONS: Individually tailored doses of vWF/FVIII concentrate according to intervention-associated bleeding risk were effective in preventing postoperative bleeding, with few complications observed. These doses may be used as guidance in routine clinical care.
Nusrat Jahan, Jae M. Lee, Khalid Shah, Hiroaki Wakimoto, "Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus", International Journal of Cancer 141, no. 8 (2017): 1671-1681. https://doi.org/10.1002/ijc.30811. This Expression of Concern is for the above article, published online on 31 May 2017, in Wiley Online Library (wileyonlinelibrary.com), and has been published by agreement between the authors, the journal's Editor-in-Chief, Christoph Plass, the Union for International Cancer Control and John Wiley & Sons, Ltd. The Expression of Concern has been agreed following concerns raised regarding figure 4g and 5d. The Control (PBS) 4X DAPI image in figure 5d was found to contain elements similar to the Control (PBS) DAPI image presented in figure 4g. The authors admitted that they had mistakenly supplied the incorrect image to represent DAPI in figure 5d. Since the original DAPI image for figure 5d is no longer available, this issue could not be resolved. The journal has decided to issue an Expression of Concern to alert the readers.
A substance countering agent especially for an abused drug or alcohol or a contraceptive agent is contained in a flexible adherent sheet or patch used to achieve the transdermal delivery of the agent through the skin of a person. The patch is limp, fragile, and non-self-supporting. The patch has a weak structure and is sufficiently limp and fragile so that the patch cannot be removed from the skin and later reapplied to the skin as a smooth planar covering. A compliance verification method is also provided for compulsory drug administration. This novel method includes providing a flexible adhesive patch containing a substance countering agent to be administered transdermally to the patient and maintaining the patch sufficiently limp and fragile so that the patch cannot be removed from the skin and later reapplied to the skin as a smooth planar covering. Prior to being applied to the skin, a supporting sheet or carrier is provided for supporting the patch in an outstretched, wrinkle-free condition. The patch is applied to the skin and the supporting sheet or carrier is removed, leaving the patch on the skin as a thin, membranous covering.
Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
The technical problems to be solved by the invention are as follows: provided is a pharmaceutical composition for preventing and/or treating acute kidney injury, and an autophagy activator. The present invention relates to a pharmaceutical composition for preventing and/or treating acute kidney injury, which comprises a compound represented by the general formula (1), a salt thereof or a prodrug thereof. In the general formula (1), A is a benzene ring which may be substituted. B is aryl which may be substituted or heteroaryl which may be substituted. X is an oxygen atom or a sulfur atom. Y is a nitrogen atom or a carbon atom. In the formula (2-1), the formula (2-2) is a single bond or a double bond when Y is a carbon atom, and is a single bond when Y is a nitrogen atom. R is R  1  Independently of one another, lower alkyl, or 2R  1  Can be bonded to each other to form a spiro or bridged structure, or 2R  1  Can be bonded to each other and constitute and containThe carbon and nitrogen atoms of the ring of Y together form a saturated, fused heterocycle. p is 0, 1 or 2. Or (R)  1  )  p  Is oxo.]